CClinicalTrials.gg
Sign In
RecruitingNCT06173440BaumanniiUpdated Dec 15, 2023

Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital

An observational study in Acinetobacter Baumannii, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2020; still recruiting 6 years 9 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
148
Ages
18 Years and older
Sex
All
01

Study summary

Colonization with imipenem-resistant Acinetobacter baumannii (IBA) is an unfavorable event for the patient, especially in intensive care. Indeed, it exposes the patient to the risk of developing serious infections, extremely difficult to treat. ABRI is a particularly resistant bacterium in the environment. When an ABRI epidemic occurs in a department as central to the hospital as a surgical resuscitation department, the control of such an event can be extremely complex. There are few clear and detailed descriptions in the literature of how to manage this type of outbreak, let alone an ABRI outbreak of this magnitude.

02

Conditions studied

  • Acinetobacter Baumannii

Keywords

  • Acinetobacter baumannii
  • Imipenem-resistant
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Major subject (≥18 years old) having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI

Inclusion criteria

  • Major subject (≥18 years old)
  • Patient having been hospitalized in the surgical resuscitation service of Hautepierre during the ABRI epidemic, between 01/05/2015 and 01/01/2019 inclusive and having been colonized and/or infected by ABRI (according to bacteriological results transmitted to the hygiene service).
  • Subject having given his/her agreement, after information, for the reuse of his/her data for the purpose of this research

Exclusion criteria

Exclusion criteria:

  • Subject having expressed his opposition to participate in the study
  • Subject under guardianship or curatorship
  • Subject under legal protection
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
148 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Retrospective description of the management of an imipenem-resistant Acinetobacter baumannii outbreak that occurred from 2015 to 2019 in a surgical intensive care unit

    Time frame: Through study completion, an average of 5 months

07

Study locations

1 of 1 sites recruiting
  • Service Equipe opérationnelle d'hygiène - CHU de Strasbourg - France
    Strasbourg, 67091, France
    • Stéphanie DEBOSCKER, MD · Contact · stephanie.deboscker@chru-strasbourg.fr · 33 3 69 55 03 10
    • Stéphanie DEBOSCKER, MD · Principal investigator
    • Thierry Lavigne, MD · Sub investigator
    • Julien Pottecher, MD, PhD · Sub investigator
    • Clémence Risser, MD · Sub investigator
    • Anne Launoy, MD · Sub investigator
    • Rosalie WIllemain, MD · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06173440
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 1, 2020
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Dec 15, 2023

Study contacts

Stéphanie DEBOSCKER, MD
Contact
stephanie.deboscker@chru-strasbourg.fr
33 3 69 55 03 10

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion